Both Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	5.17M	43.81	111.46M	-3.64	0.00
SELLAS Life Sciences Group Inc.	N/A	0.00	37.39M	-4.96	0.00

Demonstrates Paratek Pharmaceuticals Inc. and SELLAS Life Sciences Group Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%
SELLAS Life Sciences Group Inc.	0.00%	-625.6%	-76.1%

Volatility & Risk

A beta of 1.03 shows that Paratek Pharmaceuticals Inc. is 3.00% more volatile than Standard & Poor’s 500. In other hand, SELLAS Life Sciences Group Inc. has beta of 0.95 which is 5.00% less volatile than Standard & Poor’s 500.

Liquidity

Paratek Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 11.4 and 11.4 respectively. The Current Ratio and Quick Ratio of its competitor SELLAS Life Sciences Group Inc. are 1.5 and 1.5 respectively. Paratek Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to SELLAS Life Sciences Group Inc.

Analyst Ratings

Paratek Pharmaceuticals Inc. and SELLAS Life Sciences Group Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	1	1	2.50
SELLAS Life Sciences Group Inc.	0	0	0	0.00

Paratek Pharmaceuticals Inc.’s upside potential is 92.31% at a $13.5 consensus price target.

Institutional and Insider Ownership

Institutional investors held 82.6% of Paratek Pharmaceuticals Inc. shares and 25.1% of SELLAS Life Sciences Group Inc. shares. Paratek Pharmaceuticals Inc.’s share held by insiders are 2.9%. Competitively, insiders own roughly 2.25% of SELLAS Life Sciences Group Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%
SELLAS Life Sciences Group Inc.	-5.59%	-2.87%	43.22%	-68.17%	-79.14%	-79.6%

For the past year Paratek Pharmaceuticals Inc. was less bearish than SELLAS Life Sciences Group Inc.

Summary

On 8 of the 10 factors Paratek Pharmaceuticals Inc. beats SELLAS Life Sciences Group Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

SELLAS Life Sciences Group, Inc., a development-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S, a cancer immunotherapeutic agent for the treatment of hematologic cancers and solid tumor indications, including acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. It also develops NEUVAX, which is in Phase II clinical trial for the treatment of breast cancer; and Anagrelide controlled release, which has completed various clinical trials for the treatment of thrombocythemia. The company has collaboration and license agreements with Memorial Sloan Kettering Cancer Center, Advaxis Immunotherapies, Merck & Co., Inc., National Cancer Institute, and the University of Texas M.D. Anderson Cancer Center. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.